\-\ Texto\\:\\ \ \(0\)\
\-\ axial\\ contrast\\-enhanced\\ ct\\ images\\ reveal\\ a\\ large\\,\\ mildly\\ heterogeneous\\,\\ enhancing\\ right\\ hilar\\ mass\\ that\\ measures\\ 7\\.2cm\\ ap\\.\\ \\ no\\ distinct\\ calcification\\ or\\ necrosis\\ is\\ appreciated\\,\\ no\\ other\\ masses\\ or\\ nodules\\ are\\ appreciated\\.\\ the\\ mass\\ exerts\\ minimal\\ compressive\\ effect\\ on\\ the\\ superior\\ vena\\ cava\\ and\\ right\\ atrium\\.\ \(0\)\
\-\ castleman\\ disease\ \(0\)\
\-\ broad\\ differential\\ for\\ asymmetric\\ hilar\\ lymphadenopathy\\ includes\\ infection\\ \\(tuberculosis\\ or\\ other\\ granulomatous\\/infectious\\ causes\\)\\,\\ primary\\ or\\ metastatic\\ lung\\ cancer\\,\\ metastatic\\ disease\\,\\ lymphoma\\,\\ sarcoidosis\\,\\ inflammatory\\ pneumoconioses\\,\\ collagen\\ vascular\\ disease\\,\\ reactive\\ hyperplasia\ \(0\)\
\-\ 50yo\\ man\\ presents\\ for\\ follow\\-up\\ of\\ his\\ \\"castleman\\ disease\\,\\ hyaline\\ vascular\\ variant\\"\\.\\ \\ no\\ prior\\ studies\\ are\\ available\\.\ \(0\)\
\-\ if\\ the\\ mass\\ continues\\ to\\ grow\\,\\ it\\ could\\ compress\\ the\\ right\\ atrium\\/svc\\ and\\ result\\ in\\ superior\\ vena\\ cava\\ syndrome\\,\\ so\\ continued\\ monitoring\\ was\\ recommended\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ castleman\\:\\ 0\\.08929384380721372\ \(0\)\
\-\ vena\\:\\ 0\\.06464369975454438\ \(0\)\
\-\ cava\\:\\ 0\\.0642575758632884\ \(0\)\
\-\ 7\\.2cm\\:\\ 0\\.06296798874261784\ \(0\)\
\-\ granulomatous\\/infectious\\:\\ 0\\.06296798874261784\ \(0\)\
\-\ atrium\\/svc\\:\\ 0\\.06296798874261784\ \(0\)\
\-\ hilar\\:\\ 0\\.06133899781310654\ \(0\)\
\-\ appreciated\\:\\ 0\\.0594508296258425\ \(0\)\
\-\ 50yo\\:\\ 0\\.05801693745290395\ \(0\)\
\-\ pneumoconioses\\:\\ 0\\.05147200365380284\ \(0\)\
\-\ exerts\\:\\ 0\\.04906863053507989\ \(0\)\
\-\ hyaline\\:\\ 0\\.043624773020459195\ \(0\)\
\-\ compress\\:\\ 0\\.04232247618621667\ \(0\)\
\-\ vascular\\:\\ 0\\.04002576097033852\ \(0\)\
\-\ disease\\:\\ 0\\.03990678689187726\ \(0\)\
\-\ grow\\:\\ 0\\.039695870613892965\ \(0\)\
\-\ superior\\:\\ 0\\.03898205281505988\ \(0\)\
\-\ compressive\\:\\ 0\\.03777969928107383\ \(0\)\
\-\ distinct\\:\\ 0\\.03627034861202235\ \(0\)\
\-\ collagen\\:\\ 0\\.034744819324179076\ \(0\)\
\-\ atrium\\:\\ 0\\.03434418027667162\ \(0\)\
\-\ contrast\\-enhanced\\:\\ 0\\.0342154766659382\ \(0\)\
\-\ monitoring\\:\\ 0\\.033722670441031416\ \(0\)\
\-\ continues\\:\\ 0\\.031848639980549334\ \(0\)\
\-\ broad\\:\\ 0\\.03166779849494726\ \(0\)\
\-\ metastatic\\:\\ 0\\.030730134337372716\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.030073915985560046\ \(0\)\
\-\ asymmetric\\:\\ 0\\.029657709498960225\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.029075616397166056\ \(0\)\
\-\ variant\\:\\ 0\\.029075616397166056\ \(0\)\
\-\ reactive\\:\\ 0\\.028891669996434523\ \(0\)\
\-\ or\\:\\ 0\\.028614935684677358\ \(0\)\
\-\ other\\:\\ 0\\.028137693552892123\ \(0\)\
\-\ so\\:\\ 0\\.027773319562923525\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.02756922404546598\ \(0\)\
\-\ reveal\\:\\ 0\\.0271777366419303\ \(0\)\
\-\ continued\\:\\ 0\\.02628371419225883\ \(0\)\
\-\ measures\\:\\ 0\\.026117593748228352\ \(0\)\
\-\ mildly\\:\\ 0\\.02599549065280478\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.02595524909767438\ \(0\)\
\-\ mass\\:\\ 0\\.02546702157744781\ \(0\)\
\-\ nodules\\:\\ 0\\.025303706181448223\ \(0\)\
\-\ recommended\\:\\ 0\\.025303706181448223\ \(0\)\
\-\ \\,\\:\\ 0\\.025137363226605258\ \(0\)\
\-\ includes\\:\\ 0\\.024606288541705965\ \(0\)\
\-\ necrosis\\:\\ 0\\.02409357652460503\ \(0\)\
\-\ minimal\\:\\ 0\\.024031999788577126\ \(0\)\
\-\ causes\\:\\ 0\\.02376129069864151\ \(0\)\
\-\ result\\:\\ 0\\.023415601121056867\ \(0\)\
\-\ studies\\:\\ 0\\.022796435126994\ \(0\)\
\-\ could\\:\\ 0\\.022518271027361085\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.022444251119964325\ \(0\)\
\-\ ap\\:\\ 0\\.022322564068874555\ \(0\)\
\-\ calcification\\:\\ 0\\.022155611560408066\ \(0\)\
\-\ effect\\:\\ 0\\.021611130379066035\ \(0\)\
\-\ inflammatory\\:\\ 0\\.021166542458514456\ \(0\)\
\-\ masses\\:\\ 0\\.020632802842829194\ \(0\)\
\-\ available\\:\\ 0\\.020519421777427122\ \(0\)\
\-\ cancer\\:\\ 0\\.020065466174034038\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.019857407081726727\ \(0\)\
\-\ differential\\:\\ 0\\.019378284495378068\ \(0\)\
\-\ right\\:\\ 0\\.019320679480937502\ \(0\)\
\-\ enhancing\\:\\ 0\\.01914252523489114\ \(0\)\
\-\ no\\:\\ 0\\.0184380889436529\ \(0\)\
\-\ primary\\:\\ 0\\.018081316163540688\ \(0\)\
\-\ infection\\:\\ 0\\.01774297552909148\ \(0\)\
\-\ lung\\:\\ 0\\.01767970800170533\ \(0\)\
\-\ his\\:\\ 0\\.01759206448319237\ \(0\)\
\-\ syndrome\\:\\ 0\\.01745647554810458\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0174442759599249\ \(0\)\
\-\ axial\\:\\ 0\\.01741993911477051\ \(0\)\
\-\ are\\:\\ 0\\.016641055321851454\ \(0\)\
\-\ if\\:\\ 0\\.01656245309843311\ \(0\)\
\-\ prior\\:\\ 0\\.015672234087159738\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.01500096455451298\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.014712496442730306\ \(0\)\
\-\ man\\:\\ 0\\.014435227450642851\ \(0\)\
\-\ it\\:\\ 0\\.013720345603807261\ \(0\)\
\-\ large\\:\\ 0\\.013346731655936283\ \(0\)\
\-\ presents\\:\\ 0\\.012468887825056613\ \(0\)\
\-\ images\\:\\ 0\\.011709027799638243\ \(0\)\
\-\ that\\:\\ 0\\.01054271948970588\ \(0\)\
\-\ for\\:\\ 0\\.01041583069489593\ \(0\)\
\-\ ct\\:\\ 0\\.008537883238514591\ \(0\)\
\-\ was\\:\\ 0\\.007059125158669191\ \(0\)\
\-\ on\\:\\ 0\\.005170650088324486\ \(0\)\
\-\ \\(\\:\\ 0\\.005159726616027575\ \(0\)\
\-\ \\)\\:\\ 0\\.0050966978008093215\ \(0\)\
\-\ is\\:\\ 0\\.00401636270274804\ \(0\)\
\-\ the\\:\\ 0\\.003949979562960737\ \(0\)\
\-\ to\\:\\ 0\\.003050486488878473\ \(0\)\
\-\ in\\:\\ 0\\.003009980215287535\ \(0\)\
\-\ a\\:\\ 0\\.002832855727275723\ \(0\)\
\-\ and\\:\\ 0\\.002571557224745978\ \(0\)\
\-\ \\.\\:\\ 0\\.001521408689886269\ \(0\)\
\-\ of\\:\\ 0\\.0008321700056999173\ \(0\)\
